Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients

Cancer Patients ◽

Phase I Study ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.08.015 ◽

2017 ◽

Vol 147 (2) ◽

pp. 402-407 ◽

Cited By ~ 24

Author(s):

Lainie P. Martin ◽

Jason A. Konner ◽

Kathleen N. Moore ◽

Shelly M. Seward ◽

Ursula A. Matulonis ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Cancer Patients ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.

10.1200/jco.2015.33.15_suppl.5518 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5518-5518 ◽

Cited By ~ 5

Author(s):

Kathleen N. Moore ◽

Lainie P. Martin ◽

Shelly Marie Seward ◽

Todd Michael Bauer ◽

David M. O'Malley ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Trial ◽

Folate Receptor ◽

Single Agent ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Abstract CT160: A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) and endometrial cancers

10.1158/1538-7445.am2019-ct160 ◽

2019 ◽

Author(s):

Robert Wendel Naumann ◽

Denise S. Uyar ◽

Russell J. Schilder ◽

Michael A. Palumbo ◽

Venita DeAlmeida ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Folate Receptor ◽

Efficacy Study ◽

Antibody Drug Conjugate ◽

Open Label ◽

Endometrial Cancers ◽

Advanced Epithelial Ovarian Cancer ◽

A phase I study of MORAb-003, a humanized monoclonal antibody against folate receptor alpha, in advanced epithelial ovarian cancer

10.1200/jco.2008.26.15_suppl.5517 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 5517-5517 ◽

Cited By ~ 1

Author(s):

K. M. Bell-McGuinn ◽

J. A. Konner ◽

N. Pandit-Taskar ◽

S. M. Larson ◽

S. R. Gerst ◽

...

Keyword(s):

Ovarian Cancer ◽

Monoclonal Antibody ◽

Phase I ◽

Advanced Epithelial Ovarian Cancer

Phase I Study ◽

Folate Receptor ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Humanized Monoclonal Antibody ◽

Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.

10.1200/jco.2014.32.15_suppl.5571 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5571-5571 ◽

Cited By ~ 4

Author(s):

Kathleen N. Moore ◽

Joseph Ponte ◽

Patricia LoRusso ◽

Michael J. Birrer ◽

Todd Michael Bauer ◽

...

Keyword(s):

Ovarian Cancer ◽

Solid Tumors ◽

Folate Receptor ◽

Clinical Activity ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Relationship Of ◽

Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.

10.1200/jco.2015.33.15_suppl.5558 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5558-5558 ◽

Cited By ~ 8

Author(s):

Hossein Borghaei ◽

David M. O'Malley ◽

Shelly Marie Seward ◽

Todd Michael Bauer ◽

Raymond P. Perez ◽

...

Keyword(s):

Ovarian Cancer ◽

Solid Tumors ◽

Folate Receptor ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Receptor Alpha ◽

Drug Conjugate ◽

Abstract CT160: A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) and endometrial cancers

10.1158/1538-7445.sabcs18-ct160 ◽

2019 ◽

Author(s):

Robert Wendel Naumann ◽

Denise S. Uyar ◽

Russell J. Schilder ◽

Michael A. Palumbo ◽

Venita DeAlmeida ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Folate Receptor ◽

Efficacy Study ◽

Antibody Drug Conjugate ◽

Open Label ◽

Endometrial Cancers ◽

Advanced Epithelial Ovarian Cancer ◽

Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.085 ◽

2018 ◽

Vol 149 ◽

pp. 38 ◽

Cited By ~ 10

Author(s):

U.A. Matulonis ◽

K.N. Moore ◽

L.P. Martin ◽

I.B. Vergote ◽

C.M. Castro ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

10.1158/1538-7445.am2020-ct125 ◽

2020 ◽

Author(s):

R. Wendel Naumann ◽

Denise Uyar ◽

John W. Moroney ◽

Fadi S. Braiteh ◽

Russell J. Schilder ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Folate Receptor ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Receptor Alpha ◽

Drug Conjugate ◽

138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)

10.1136/ijgc-2020-igcs.119 ◽

2020 ◽

Author(s):

R Naumann ◽

F Braiteh ◽

J Diaz ◽

E Hamilton ◽

S Diab ◽

...

Keyword(s):

Ovarian Cancer ◽

Dose Escalation ◽

Folate Receptor ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Dose Escalation Study ◽

Receptor Alpha ◽

Drug Conjugate ◽